Zoetis (ZTS) reported $2.32 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 4.7%. EPS of $1.40 for the same period compares to $1.24 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $2.3 billion, representing a surprise of +0.68%. The company delivered an EPS surprise of +2.19%, with the consensus EPS estimate being $1.37.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Zoetis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- U.S. $1.26 billion compared to the $1.28 billion average estimate based on four analysts. The reported number represents a change of +3.8% year over year.
- Geographic Revenues- International Revenue: $1.04 billion compared to the $1.01 billion average estimate based on four analysts. The reported number represents a change of +5.8% year over year.
- Geographic Revenues- International - Companion Animal: $562 million versus the three-analyst average estimate of $552.54 million. The reported number represents a year-over-year change of +10.9%.
- Geographic Revenues- U.S.- Livestock: $249 million versus $254.14 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.8% change.
- Revenues- Contract Manufacturing & Human Health: $21 million compared to the $20.40 million average estimate based on five analysts. The reported number represents a change of +5% year over year.
- Revenues- Companion Animal: $1.57 billion versus the four-analyst average estimate of $1.57 billion. The reported number represents a year-over-year change of +8.4%.
- Revenues- Livestock: $726 million versus the four-analyst average estimate of $719.48 million. The reported number represents a year-over-year change of -2.6%.
- Revenues- Livestock - Poultry: $117 million compared to the $133.46 million average estimate based on two analysts. The reported number represents a change of -7.9% year over year.
- Revenues- Companion Animal - Horses: $93 million compared to the $75.95 million average estimate based on two analysts. The reported number represents a change of +5.7% year over year.
- Revenues- Companion Animal - Dogs and Cats: $1.48 billion compared to the $1.50 billion average estimate based on two analysts. The reported number represents a change of +8.6% year over year.
- Revenues- Livestock - Swine: $128 million versus $138.56 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.9% change.
- Revenues- Livestock - Cattle: $399 million compared to the $376.59 million average estimate based on two analysts. The reported number represents a change of -0.5% year over year.
Shares of Zoetis have returned +4% over the past month versus the Zacks S&P 500 composite's +3.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpZoetis Inc. (ZTS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
